RANKL Protein, Cynomolgus, Recombinant (hFc Tag)

Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein that belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.

1. Immobilized Cynomolgus S4-Fc3L3-TNFSF11 at 10 μg/ml (100 μl/well) can bind biotinylated human TNFRSF11B-His (Cat:PH50962M2), The ECof biotinylated human TNFRSF11B-His (Cat:PH50962M2) is 7.94-18.52 ng/ml. 2. The bioactivity of RANKL was determined by measuring the ability of RANKL to induce TRAP activity in RAW264.7 cells. The EDfor this effect is typically 7-35 ng/mL.

Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.

TNF Superfamily proteins, CD Molecule proteins, Cancer proteins, Immunotherapy proteins, Cytokine Proteins, Growth Factor proteins, Biological Target proteins

The recombinant cynomolgus TNFSF11 comprises 442 amino acids and has a calculated molecular mass of 48.9 KDa. The apparent molecular mass of the protein is approximately 55 KDa in SDS-PAGE.

In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. Stable for 1 year at -20°C or below from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and opening the cap. For long-term storage, aliquot and store at -20°C or below. Avoid repeated freeze-thaw cycles.